Back
Insmed Incorporated (INSM)
BiotechnologyINSM · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$123.85
−0.03%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$-6.42
ROE
-294.5%
Gross margin
81.8%
Debt/Equity
1.05x
Revenue growth
229.6%
Insmed Incorporated — company intelligence
Earnings surprises
Q2 2026$-0.06 vs $-0.80 est+92.5%
Q1 2026$-0.76 vs $-0.98 est+22.3%
Q4 2025$-1.54 vs $-1.32 est-17.0%
Q3 2025$-1.75 vs $-1.37 est-28.1%
Analyst consensus · 30 analysts
29 Buy1 Hold0 Sell
Updated Aug 20, 2026
Insider activity · 90 days
2 buys20 sellsnet -62,470 shares
Lewis WilliamSell 5,872 · Jul 23, 2026
Lewis Williamother 6,260 · Jul 23, 2026
Lewis Williamother 4,440 · Jul 23, 2026
Recent SEC filings
4 — Insider transaction reportAug 12, 2026
4 — Insider transaction reportAug 7, 2026
8-K — Material event reportAug 6, 2026
Latest news
Biotech Is Booming, But These 2 Stocks Missed the Memo — Benzinga · 5d ago
JP Morgan Maintains Overweight on Insmed, Lowers Price Target to $175 — Benzinga · 2w ago
Truist Securities Reiterates Buy on Insmed, Raises Price Target to $195 — Benzinga · 2w ago
$1000 Invested In Insmed 5 Years Ago Would Be Worth This Much Today — Benzinga · 2w ago
HQH: After Biotech's Breakout Year, This Healthcare CEF Still Trades Below NAV; Buy — SeekingAlpha · 2w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.